We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.

Delisted

BHVN was delisted on the 3rd of October, 2022.

2 hedge funds and large institutions have $27.2M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more capital invested

Capital invested by funds: $21.3M → $27.2M (+$5.92M)

0% more funds holding

Funds holding: 22 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
2
Holders Change
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

BHVN Hedge Fund Activity: Q1 2024 in Review

2 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q1 2024, worth a combined $27.2M — up 28% from $21.3M a quarter earlier.

Fund positioning in BHVN was balanced in Q1 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $27.2M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q1 2024, up 28% quarter-over-quarter.
  • 0 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q1 2024 and 0 closed out.

Based on aggregated 13F filings for Q1 2024.